Literature DB >> 3559612

Oligodendroglioma: an analysis of 42 cases.

I M Wilkinson, J R Anderson, A E Holmes.   

Abstract

This paper presents the clinical and pathological data obtained from 42 patients with oligodendroglioma diagnosed over a 20 year period at Addenbrooke's Hospital, Cambridge. In all cases the diagnosis was established unequivocally by histological examination. The principal conclusions of this study were: (1) the outcome was not as favourable as anticipated, nine patients dying within 1 year of diagnosis, and only 10 patients surviving 5 years, (2) age at the time of diagnosis was the single most important prognostic factor, patients under 45 years at diagnosis having a significantly greater survival time than older patients, (3) two other factors had a significantly adverse effect on prognosis, namely the presence of a focal neurological deficit at the time of diagnosis and the presence of nuclear pleomorphism in the tumour when examined histologically, (4) although cells containing glial fibrillary acidic protein were demonstrated in almost every tumour, their number and distribution did not appear to influence the prognosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3559612      PMCID: PMC1031795          DOI: 10.1136/jnnp.50.3.304

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Grading of oligodendrogliomas.

Authors:  M T Smith; C L Ludwig; A D Godfrey; V W Armbrustmacher
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

2.  Role of radiation therapy in the treatment of cerebral oligodendroglioma: an analysis of 57 cases and a literature review.

Authors:  D P Reedy; J W Bay; J F Hahn
Journal:  Neurosurgery       Date:  1983-11       Impact factor: 4.654

3.  Histologic factors of prognostic significance in the glioblastoma multiforme.

Authors:  P C Burger; R T Vollmer
Journal:  Cancer       Date:  1980-09-01       Impact factor: 6.860

4.  A long term study of patients with oligodendrogliomas. Follow-up of 50 cases, including Dr. Harvey Cushing's series.

Authors:  M Roberts; W J German
Journal:  J Neurosurg       Date:  1966-04       Impact factor: 5.115

5.  Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas.

Authors:  H W Chin; J J Hazel; T H Kim; J H Webster
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

6.  Expression of glial fibrillary acidic protein in immature oligodendroglia.

Authors:  B H Choi; R C Kim
Journal:  Science       Date:  1984-01-27       Impact factor: 47.728

7.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.

Authors:  C H Chang; J Horton; D Schoenfeld; O Salazer; R Perez-Tamayo; S Kramer; A Weinstein; J S Nelson; Y Tsukada
Journal:  Cancer       Date:  1983-09-15       Impact factor: 6.860

8.  Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma.

Authors:  M J Herpers; H Budka
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

  8 in total
  11 in total

1.  Extradural cord compression due to metastatic oligodendroglioma.

Authors:  Jeff Garner; Yehya Morcos; Mohammed Bari
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

2.  Oligoastrocytomas: a clinicopathological study of 52 cases.

Authors:  H G Krouwer; S G van Duinen; W Kamphorst; P van der Valk; A Algra
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

3.  Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.

Authors:  A Boiardi; A Silvani; A Pozzi; M Farinotti; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

4.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

5.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 6.  Oligodendrogliomas: clinicopathological correlations.

Authors:  J M Kros
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Uniform lineage of oligodendrogliomas.

Authors:  S M de la Monte
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

8.  Blood flow and metabolism of oligodendrogliomas: a positron emission tomography study with kinetic analysis of 18F-fluorodeoxyglucose.

Authors:  K Mineura; H Shioya; M Kowada; T Ogawa; J Hatazawa; K Uemura
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

9.  The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas.

Authors:  M R Wacker; T Hoshino; D K Ahn; R L Davis; M D Prados
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  The treatment of cerebral oligodendrogliomas with particular reference to features indicating malignancy: report of seventy-seven cases.

Authors:  M Turgut; K Tahta; O E Ozcan; B Onol
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.